Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Abstract Text:

Kathleen Gondek,Pierre-Philippe Sagnier,Kim Gilchrist,J Michael Woolley,

Assessing patient-reported outcomes (PROs) in clinical trials is of interest to clinicians, patients, regulators, and industry. The use and impact of PROs is a growing area of methodologic research, particularly as they relate to tumor types, biomarkers, and various patient populations and cultures. Both the US Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products in recent guidance have acknowledged the need to account for treatment-related impact on patient symptoms and/or health-related quality of life (HRQOL). Clinical research likely reflects the informative value of PROs. A search of www.clinicaltrials.gov, the FDA Web site, and product package inserts was conducted to assess the inclusion of symptom assessment and HRQOL within industry-sponsored clinical trials in cancer and approved cancer therapies and their respective product labels. Overall, there were 2,704 industry-sponsored oncology trials, of which 322 (12%) included a PRO measure. Of the 70 FDA new or revised labels, only six package inserts include PRO data. Symptoms were assessed uniformly across the phases of clinical trials, whereas HRQOL assessment increased in the later phases of clinical trials. Collecting PRO data can enhance our understanding of cancer burden and the impact of interventions on patients' lives.

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Publishing Authors By Initials

K Gondek,PP Sagnier,K Gilchrist,JM Woolley,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Journal Published:

PUBLICATION TYPE: Review

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 5087-93

Journal Abbreviation:

ISSN: 1527-7755

DAY: 10

MONTH: Nov

YEAR: 2007

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.

AFFILIATION: Bayer Corporation, West Haven, CT 06516, USA. kathleen.gondek@bayer.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels Related Publications

• Asymmetric interlimb transfer of concurrent adaptation to opposing dynamic forces.
• Biologic activity of adriamycin (NSC-123127) in microbial systems.
• Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
• DNA-templated nanotube localization.
• DNA-templated three-branched nanostructures for nanoelectronic devices.
• Electrically actuated, pressure-driven liquid chromatography separations in microfabricated devices.
• Electrostatic interactions at charged lipid membranes. Hydrogen bonds in lipid membrane surfaces.
• Estrogen mobilizes a subset of estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1.
• Femoral venous thrombosis in a 5-week old with diabetic ketoacidosis and a femoral venous catheter.
• In-channel atom-transfer radical polymerization of thermoset polyester microfluidic devices for bioanalytical applications.
• Isolation of some crystalline yellow peptides from enzymic digests of dinitrophenyl insulin and dinitrophenyl trypsinogen.
• Location of the pirouette gene in Mus musculus.
• Mitomycin C: experience in the United States, with emphasis on gastric cancer.
• Morphological sex differences and laterality in the prepubertal medial amygdala.
• Pharmacological properties of some antimetabolites of serotonin having unusually high activity on isolated tissues.
• Phase-changing sacrificial layer fabrication of multilayer polymer microfluidic devices.
• Phase-changing sacrificial materials for interfacing microfluidics with ion-permeable membranes to create on-chip preconcentrators and electric field gradient focusing microchips.
• Purification of an influenza virus substrate, and demonstration of its competitive antagonism to apple pectin.
• Rapid prototyping of poly(methyl methacrylate) microfluidic systems using solvent imprinting and bonding.
• Sacrificial layer microfluidic device fabrication methods.
• Spontaneous basophilic tumors of the pituitary glands in gonadectomized mice.
• Stabilization of folded peptide and protein structures via distance matching with a long, rigid cross-linker.
• Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART.
• Studies on the structure of lycomarasmin.
• Synthesis and determination of lycomarasmin activity of some derivatives of aspartic acid.
• The adrenal cortex and its tumors.
• The binding of a neutral aromatic molecule to a negatively-charged lipid membrane I. Thermodynamics and mode of binding.
• The emotional aspects of physical disease.
• Therapy in the private practice of psychiatry.
• Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Use of tamsulosin in patients with urinary calculi to increase spontaneous stone passage.